Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascend: DT120 in Major Depressive Disorder
NCT07592689Phase 3Recruiting
- Sponsor
- Definium Therapeutics
- Start
- May 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 3 trial of lysergic acid diethylamide D-tartrate in major depressive disorder (MDD), sponsored by Definium Therapeutics. Started May 2026; status: recruiting.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07592689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592689.